Phage Therapy Market Report Scope & Overview:

Phage Therapy Market Size is valued at USD 1.27 Billion in 2025 and is projected to reach USD 1.86 Billion by 2035, growing at a CAGR of 3.91% during the forecast period 2026–2035.

The Phage Therapy Market analysis report provides a broad overview of bacteriophage-based therapeutics, with human, veterinary, and agricultural applications included. The growth prospects for the market are driven by the increased prevalence of antibiotic resistance, the use of precision medicine, phage engineering, and expanded clinical and non-human uses from 2026 to 2035.

Phage therapy treatments exceeded 120,000 applications in 2025, driven by growing use in human, veterinary, and agricultural sectors as an alternative to antibiotics.

Market Size and Forecast:

• Market Size in 2025: USD 1.27 Billion

• Market Size by 2035: USD 1.86 Billion

• CAGR: 3.91% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

Phage Therapy Market Trends:

• Rising antibiotic resistance and increasing prevalence of bacterial infections are accelerating adoption of phage-based therapeutics.

• Growing investment in phage research, engineering, and clinical trials is enhancing efficacy and safety of treatments.

• Expanding applications in human health, veterinary care, agriculture, and food safety are broadening market opportunities.

• Advances in delivery systems, formulation technologies, and precision targeting are improving therapeutic outcomes and patient compliance.

• Regulatory support and compassionate-use programs are facilitating faster market access and clinical adoption.

• Increasing collaborations between biotech firms, research institutions, and agricultural companies are boosting innovation and commercialization.

U.S. Phage Therapy Market Insights:

The U.S. Phage Therapy Market is projected to grow from USD 0.44 Billion in 2025 to USD 0.60 Billion by 2035, at a CAGR of 2.99%. The market is driven by increasing antibiotic resistance, the clinical adoption of phage-based therapeutics, the sophistication of biotech infrastructure in developed markets, robust investment in research and development and regulatory regimes fostering access to novel therapeutics.

Phage Therapy Market Growth Drivers:

• Rising antibiotic resistance and demand for targeted therapeutics driving adoption of phage-based treatments.

Antibiotic resistance and the need for targeted therapy are major factors driving the Phage Therapy Market growth. Phage therapy is increasingly being used as it is more precise and effective against bacterial infections. It has less dependence on traditional antibiotics and is effective against resistant bacterial strains. Phage therapy is being increasingly used in hospitals, veterinary clinics, and farms as a means of infection control. The need for research and awareness of alternative antibiotics are factors driving the market.

Over 18% of hospitals and veterinary clinics had adopted phage therapies by 2025, driven by rising antibiotic resistance and demand for targeted treatments.

Phage Therapy Systems Market Restraints:

• High development costs and stringent regulatory approvals for phage therapies limiting rapid clinical and commercial adoption.

High development costs and regulatory hurdles are some of the major restraints for the Phage Therapy Market. For example, phage therapy development requires a lot of investment in research and development, and clinical trials and production processes Moreover, the regulation of phage therapy is complex, and the rules differ from region to region. Many farmers and practitioners choose conventional antibiotics due to their low cost and the presence of well-established guidelines for administration. Hence, financial limitations can restrict the evolution of phage therapy.

Phage Therapy Market Opportunities:

• Growing investments in phage research and biotechnology creating opportunities for innovative antibacterial and therapeutic solutions.

Investments in research on phages and biotechnologies are creating a tremendous opportunity for the Phage Therapy Market to grow. Hospitals, veterinary clinics, and agricultural industries are increasingly looking to incorporate phage therapies to treat antibiotic-resistant diseases. Advances in the development of engineered phages, formulation, and precise delivery systems are increasing the efficacy of the treatment. Strategic partnerships between biotechnologies, research, and regulatory bodies are likely to increase the adoption of the treatment, thereby increasing the scope of the market to grow in the future.

Over 22% of biotech R&D funding in 2025 was directed to phage research, accelerating therapeutic development and adoption.

Phage Therapy Market Segmentation Analysis:

• By Phage / Product Type, dsDNA Bacteriophage held the largest market share of 38.45% in 2025, while Phage Cocktails / Engineered Preparations are expected to grow at the fastest CAGR of 5.42% during 2026–2035.

• By Administration / Route, Injectable / Surgical Administration accounted for the highest market share of 41.32% in 2025, and Oral administration is projected to register the fastest CAGR of 5.08% through 2026–2035.

• By Application / Use Case, Human Therapeutics dominated with a 42.56% market share in 2025, while Agriculture & Crop Protection is expected to grow at the fastest CAGR of 6.02% during the forecast period.

• By End-User / Customer Type, Hospitals & Clinics captured the highest market share of 44.68% in 2025, whereas Agricultural Enterprises are anticipated to expand at the fastest CAGR of 5.97% through 2026–2035.

• By Target Bacterial Indication / Disease, Urinary Tract Infections held the largest share of 36.84% in 2025, while Chronic Conditions are expected to grow at the fastest CAGR of 5.68% during the forecast period.

By Phage / Product Type, dsDNA Bacteriophage Dominated While Phage Cocktails / Engineered Preparations Are Fastest Growing:

The dsDNA Bacteriophage segment dominated the market in 2025, due to the high utilization of dsDNA bacteriophages for human therapeutics, veterinary and research purposes. More than 45,000 treatments have also been performed around the world with dsDNA phages, demonstrating their currently accepted use in clinical settings and effectiveness against common bacterial pathogens.

The Phage Cocktails / Engineered Preparations is the fastest-growing segment, due to increasing demand for multi-target phage therapies or precision-engineered solutions. There were ultimately over 12,000 treatments in trials and pilot programs by 2025 suggestive of rapid iterative innovation and accelerated adoption in advanced therapeutic development.

By Administration / Route, Injectable / Surgical Administration Dominated While Oral Is Fastest Growing:

Injectable / Surgical Administration segment dominated the market due to their administration directly at infection cite and elevated clinical efficiency particularly at hospitals and veterinary surgical theatres. In 2025, more than 52,000 injectable treatments were administered at major healthcare centers via injection as the leading delivery mode.

The Oral administration is the fastest-growing segment, with patient willingness and ease of usability for them and their potential use in agriculture and aquaculture driving this growth. Over 18000 oral therapies filed in 2025, suggesting growing uptake among non-clinical environments and homeotherapeutic settings.

By Application / Use Case, Human Therapeutics Dominated While Agriculture & Crop Protection Is Fastest Growing:

Human Therapeutics segment dominated the market, owing to the increasing case of antibiotic-resistant infections and growth in its clinical usage. In 2025, human healthcare dominated the market as the leading segment with more than 60,000 therapeutic treatments administered.

Agriculture & Crop Protection is the fastest-growing segment, motived by the necessity for increased sustainable disease control and decreased use of chemical pesticides. In 2025, greater than 15,000 phage applications were applied to crop fields and horticultural initiatives, suggesting awareness of the advantages they offer as communities seek biocontrol alternatives.

By End-User / Customer Type, Hospitals & Clinics Dominated While Agricultural Enterprises Are Fastest Growing:

Hospitals & Clinics segment dominated the market due to early adoption of phage therapies, particularly in cases of antibiotic-resistant infections and complex clinical conditions. With over 55,000 treatments carried out in hospitals in 2025 this was the largest end-user segment.

Agricultural Enterprises are the fastest-growing, supported by the need for environmental-friendly bacterial control of crops and livestock. In 2025, the implementation of over 14,000 phage applications was observed on farms and food production units, indicating quick commercialization in the agricultural space.

By Target Bacterial Indication / Disease, Urinary Tract Infections Dominated While Chronic Conditions Are Fastest Growing:

Urinary Tract Infections (UTIs) dominated the market due to high prevalence rates and established success of phage therapies for the treatment of these resistant strains. Already in 2025, over 38,000 UTI treatments were delivered, thereby further strengthening the market-leading position of this segment.

Chronic Conditions, including biofilm-associated infections and recurring bacterial infections, are the fastest-growing segment. As a result of growing clinical trials, enrichment of existing phage cocktails and increased demands for alternative therapeutics outside conventional antibiotics, over 11,000 phage treatments for chronic infections were logged in 2025.

Phage Therapy Market Regional Analysis:

North America Phage Therapy Market Insights:

The North America Phage Therapy Market is dominated, holding a 41.87% share in 2025, due to the rise in antibiotic resistance and the early adoption of phage-based therapies. More than 50,000 treatments were administered in hospitals, clinics and research institutions around the world. Other factors driving the market include advanced biotechnology capabilities, high R&D investments and presence of key phage therapy companies. North America is a well-established market characterized by high rates of clinical adoption, supportive regulations and innovation in phage engineering and therapy development.

U.S. Phage Therapy Market Insights:

The U.S. Phage Therapy Market is fuelled by increasing usage in hospitals, veterinary clinics, and agricultural settings. It is the country’s mature biotechnology infrastructure, widely available R&D capabilities and early-stage government regulation that also drive leadership positions. Ongoing developments concerning engineered phages, delivery systems, and clinical trials will help maintain the domination of the U.S. As such a North American market leader in this regard.

Asia-Pacific Phage Therapy Market Insights:

Asia-Pacific is the fastest-growing region in the Phage Therapy Market, projected to expand at a CAGR of 5.29% during 2026–2035. Growth in the market is due to rising antibiotic resistance, phage therapeutics adoption in the human, animal, and agriculture sectors, and government initiatives for the development of biotechnology. Investment in clinical trials, research, and phage engineering technologies is also contributing to market penetration. Growing biotech facilities and awareness about alternative antibacterial therapies are key growth drivers for the market in the region.

China Phage Therapy Market Insights:

The China Phage Therapy Market is driven by escalating antibiotic resistance, increased use in medical institutions, veterinary clinics, and farming practices, and robust government backing for biotechnology. Investments in phage research and clinical trials, and local manufacturing capabilities, combined with awareness of alternative antibacterial agents, ensure China is an important contributor to Asia-Pacific market development.

Europe Phage Therapy Market Insights:

Europe is a key region in the Phage Therapy Market, due to the increased antibiotic resistance and rising utilization of phage therapeutics in human, animal & agriculture. Government initiatives, research collaborations, and investment in advanced phage engineering and clinical trials are driving this growth. The European market acts as a significant contributor to the phage therapy market owing to factors such as expanding biotechnology facilities, regulations, and incorporation of precision delivery systems which help in driving the growth.

Germany Phage Therapy Market Insights:

Germany is a key market in the Europe Phage Therapy Market, backed by advanced biotechnology infrastructure and clinical research capabilities. This growth can be attributed to the widespread use of phage therapy in hospitals, animal healthcare, and agriculture; government-funded phage research programs; clinical trials; and the association of biotech companies with academic research for innovative therapies.

Latin America Phage Therapy Market Insights:

The Latin America Phage Therapy Market is growing attributed to the emergence of resistance to antibiotics and the growing use of phage-based therapies. Countries such as Brazil, Mexico, and Argentina are increasing the use of phage-based therapies for clinical, veterinary, and agricultural practices. This is attributed to the government’s efforts to develop biotechnology and the growing use of alternative medicine.

Middle East and Africa Phage Therapy Market Insights:

The Middle East & Africa Phage Therapy Market is growing due to the need to combat antibiotic resistance and the need for alternative antibacterial agents. Countries such as Saudi Arabia, UAE, and South Africa are investing in biotechnology, clinical research, and veterinary uses. This is due to government initiatives and awareness of alternative antibacterial agents.

Phage Therapy Market Competitive Landscape:

Adaptive Phage Therapeutics is a clinical-stage biotech company developing precision bacteriophage therapies to treat multidrug-resistant bacterial infections. Established in 2016, it was the first to break ground with PhageBank, a large-scale repository of phages for matching specific phages to emerging pathogens for use therapeutically. Phagelux's leadership in adaptive phage development comes from its ability to quickly screen and deploy personalized phage solutions against superbugs. With a sophisticated phage library and unique financial positioning, the company is on track to become a leading innovator in targeted antibacterial therapies.

• In December 2025, Adaptive Phage Therapeutics expanded its Series B funding, securing significant investment to accelerate clinical phage programs targeting antibiotic-resistant infections. This development strengthens its pipeline, enhances personalized phage therapy, and reinforces its leadership in adaptive phage solutions.

Armata Pharmaceuticals is a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and hard-to-treat infections. The company’s end-to-end, vertically integrated platform spans discovery and synthetic biology optimization to the development of dedicated cGMP production capabilities in-house enabling it to generate customized phage cocktails against leading pathogens including Pseudomonas aeruginosa and Staphylococcus aureus. Armata's end-to-end pipeline and advanced manufacturing capabilities position it as a world leader in advancing phage therapies through the clinic and toward regulatory approval in key markets.

• In November 2025, Armata Pharmaceuticals commissioned a state-of-the-art cGMP phage manufacturing facility, enabling high-purity production of therapeutic phages. This development supports clinical trials, regulatory readiness, and reinforces the company’s leadership in pathogen-specific bacteriophage therapies.

Locus Biosciences is a clinical-stage bio-pharmaceutical company pioneering CRISPR-enhanced bacteriophage therapies for the treatment of antibiotic-resistant bacterial infections. Locus offers precision antibacterials using its proprietary engineered phage platform and the high-throughput discovery capabilities coupled with synthetic biology and computational optimization. LBP-EC01, the lead candidate, has progressed through Phase 1b and Phase 2 clinical trials in urinary tract infections. With strategic collaborations, funding and new technologies at its disposal, Locus is avant-garde for next-generation engineered phage therapeutics.

• In October 2025, Locus Biosciences reported positive Phase 2 trial results for its CRISPR-enhanced phage therapy LBP‑EC01, meeting safety and pharmacokinetic endpoints. This development advances clinical progression and reinforces the company’s leadership in engineered phage therapeutics.

Phage Therapy Market Key Players:

Some of the Phage Therapy Market Companies are: 

• Adaptive Phage Therapeutics

• Armata Pharmaceuticals

• Locus Biosciences

• Intralytix, Inc.

• Pherecydes Pharma

• EnBiotix, Inc.

• Eligo Bioscience

• ContraFect Corporation

• Micreos B.V.

• Nextbiotics

• Phagomed Biopharma GmbH

• PhagePro, Inc.

• TechnoPhage

• Proteon Pharmaceuticals

• Eliava BioPreparations

• Fixed-Phage Ltd.

• BiomX Ltd.

• iNtODEWORLD

• Phagelux

• InnoPhage Ltd.